# 3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)

> **NIH NIH R44** · CENTERLINE BIOMEDICAL, INC. · 2020 · $806,827

## Abstract

Project Summary/Abstract
This SBIR Phase II project will advance the commercialization of our 3D guidance, navigation, and control (3D-
GNC) system to improve stent-graft (SG) deployment during endovascular aortic aneurysm repair (EVAR) by
overcoming limitations of 2D x-ray fluoroscopy (“fluoro”). 3D-GNC will increase safety, effectiveness, and
efficiency as a result of better visualization, particularly when deploying SGs within hostile aortic anatomy, with
challenges such as short and/or angled landing zones. True 3D (360°), radiation-free GNC that is not limited
by a 2D display will decrease radiation to patients and OR staff, reduce procedure time, and enable accurate
SG positioning leading to fewer postoperative complications or need for re-intervention. Converting this
innovation to a product will expand the patient population eligible for EVAR, particularly those with highly
unfavorable aortic anatomy, as the demand and utilization of the minimally-invasive approach continues to rise.
In Phase I, a 3D-GNC research prototype was developed and integrated with our Intra-Operative Positioning
System (IOPS). The Guidance subsystem digitally augments the patient-specific aortic model to the surgical
field using a modern, self-contained augmented/mixed reality head mounted display. Navigation accurately
tracks in real-time the 3D position and orientation (P&O) of a sensor-equipped wire (IOPS-SG1 Wire) for
projecting a SG hologram in spatial registration with the aorta hologram. Our holographic Control panel
suggests P&O maneuvers as the delivery system approaches the aneurysm's proximal neck landing zone.
Phase I results met all acceptance criteria for Specific Aims in terms of 1) usability in bench testing by a focus
group of 10 surgeons, 2) accuracy for SG delivery system positioning in six 3D-printed aortic models with
complex anatomy, and 3) benefits of 3D-GNC in our preclinical protocol relative to fluoro: radiation dose and
contrast dose (100% decrease), procedure time (56.4% decrease), and orientation accuracy (41.5% increase).
In Phase II, we will develop, verify and validate the 3D-GNC system based on Phase I outcomes, on-going
user feedback, and our quality management system (QMS). We will evaluate usability at 3 leading aortic
medical centers (Aim 1) and verify accuracy on the bench by deploying SGs from at least 2 manufacturers in
3D-printed models using designed controlled system components (Aim 2). After IDE and IRB clearance, we will
conduct a first-in-human study in Aim 3 to demonstrate that use of 3D-GNC as an adjunct to and confirmed by
fluoro is safe and effective and can lower radiation dose, while obtaining feedback for design finalization. All
development will be in compliance with our QMS, toward preparation for FDA premarket clearance (Aim 4).
Overcoming limitations of fluoro and improving SG placement will pave the way to realizing the full clinical and
economic benefits of EVAR over highly invasive open surgical repair. ...

## Key facts

- **NIH application ID:** 10001634
- **Project number:** 5R44HL139290-03
- **Recipient organization:** CENTERLINE BIOMEDICAL, INC.
- **Principal Investigator:** Vikash Goel
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $806,827
- **Award type:** 5
- **Project period:** 2018-02-15 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10001634

## Citation

> US National Institutes of Health, RePORTER application 10001634, 3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR) (5R44HL139290-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10001634. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*